Saudi Arabia Next Generation Sequencing (NGS) Market Size, Share & Forecast (2024-2031)

The Saudi Arabia Next Generation Sequencing (NGS) market is witnessing rapid growth, driven by advances in genomics, an increasing prevalence of cancer, and expanding applications of NGS across clinical and research settings. Valued at USD 24.4 million in 2023, the market is projected to reach USD 25.5 million in 2024 and further expand to USD 50 million by 2031, growing at a CAGR of 10.1% during the forecast period. This strong momentum highlights Saudi Arabia's growing focus on precision medicine, advanced healthcare technologies, and genomic research as part of its Vision 2030 initiatives.

Download Sample Report Here : https://www.meticulousresearch.com/download-sample-report/cp_id=6002

Market Overview

Next Generation Sequencing has transformed genomic analysis by enabling high-throughput, cost-effective, and accurate sequencing of DNA and RNA. In Saudi Arabia, the demand for NGS is expanding due to its growing use in oncology, reproductive health, infectious diseases, and genetic disorder research. The technology's ability to decode vast amounts of genetic information quickly is making it indispensable in both research institutions and clinical laboratories.

The Saudi government's increasing investment in healthcare digitization and genomic medicine, combined with rising collaborations among global and local players, has further fueled market development. Institutions such as King Abdulaziz University have undertaken genome research using portable sequencing devices, reflecting the nation's commitment to adopting cutting-edge genomic technologies.

Rising Cancer Burden and Role of NGS in Treatment

Cancer continues to be one of the leading causes of death in Saudi Arabia, posing a major challenge to public health. According to GLOBOCAN, cancer incidence in the country is projected to reach nearly 39,900 cases by 2030, up from 28,113 cases in 2022. Similarly, cancer-related deaths are expected to rise from 13,400 in 2022 to over 42,000 by 2045. This increasing disease burden is pushing healthcare providers to integrate advanced diagnostic and treatment tools like NGS.

NGS enables clinicians to identify genetic mutations, molecular signatures, and biomarkers associated with different cancer types, providing crucial insights for developing personalized therapies. It also assists in tumor classification, drug resistance monitoring, and therapy selection. The adoption of NGS in oncology is improving patient outcomes by allowing for precise, targeted, and effective treatment strategies.

Expanding Use of NGS in Clinical Applications

NGS technology is revolutionizing clinical diagnostics due to its ability to sequence entire genomes or specific gene panels quickly and efficiently. By detecting both common and rare genetic variants, it helps researchers understand disease mechanisms at a molecular level. In Saudi Arabia, clinical adoption is growing rapidly, particularly in oncology, reproductive health, and infectious disease testing.

As sequencing costs continue to decline, the use of NGS in routine clinical diagnostics is becoming more feasible. The technology's integration into liquid biopsy testing for early cancer detection and reproductive health screening is expanding its potential. In the coming years, the scope of NGS is expected to diversify further, supported by the growing discovery of new biomarkers and genetic mutations relevant to precision medicine.

Browse in Depth : https://www.meticulousresearch.com/product/saudi-arabia-ngs-market-6002

What is Driving the Growth of Personalized Medicine in Saudi Arabia?

One of the most promising applications of NGS lies in personalized medicine, an approach that tailors treatment based on a patient's genetic profile. Precision medicine moves away from the "one-size-fits-all" model by using genomic data to identify disease-specific variations and guide treatment decisions. In Saudi Arabia, precision medicine is gaining attention as part of broader healthcare reforms aimed at improving patient outcomes and reducing trial-and-error in drug prescriptions.

NGS plays a critical role in this transformation. By enabling rapid sequencing of multiple genes, NGS allows for the identification of actionable genetic alterations that can influence treatment choices. This capability supports the development of targeted therapies, particularly in oncology and genetic disorders. As awareness of precision medicine increases and genomic databases expand, Saudi Arabia is well-positioned to become a regional leader in genomics-driven healthcare.

Emerging Trend: Portable and Real-Time Sequencing

Technological advancements are making sequencing faster, more affordable, and more accessible. The introduction of portable sequencing devices has been a game-changer in the Saudi NGS landscape. These handheld devices, often based on nanopore technology, allow for real-time analysis of DNA without requiring large laboratory infrastructure.

Portable sequencers are now being used for applications such as pathogen detection, plant genome analysis, and genetic testing in field conditions. Their affordability-capable of sequencing entire genomes for under USD 1,000-makes them particularly appealing for academic and research institutions across Saudi Arabia.

A notable example includes research conducted at King Abdulaziz University, where nanopore-based sequencing was employed for genotyping studies. This shift toward decentralized sequencing technology reflects a broader trend of innovation aimed at improving accessibility and efficiency in genomics research.

Buy the Complete Report with an Impressive Discount: https://www.meticulousresearch.com/view-pricing/1319

Market Segmentation Insights

In 2024, consumables accounted for the largest share of the Saudi Arabia NGS market, representing 62.6% of total revenue. This dominance is attributed to the frequent use of reagents, kits, and target enrichment products in sequencing workflows. The segment is expected to reach USD 31.8 million by 2031, growing at a CAGR of 10.3%.

Targeted genome sequencing is the leading sequencing type due to its lower cost, faster turnaround time, and simpler data analysis. It is particularly valuable in cancer diagnosis and genetic disease studies, where identifying somatic mutations is critical.

In terms of application, research and other applications hold the majority share, driven by extensive adoption in academic and pharmaceutical research. This segment is projected to reach USD 29.3 million by 2031. Hospitals and diagnostic laboratories are the largest end users, supported by expanding healthcare infrastructure and public-private investments under Vision 2030.

Competitive Landscape and Key Developments

The Saudi Arabia NGS market is competitive, with several global players actively expanding their presence. Key companies include Illumina, Thermo Fisher Scientific, QIAGEN, Agilent Technologies, Pacific Biosciences, Oxford Nanopore Technologies, and F. Hoffmann-La Roche. These firms are introducing innovative platforms, consumables, and software solutions tailored to meet clinical and research needs.

Recent developments highlight growing innovation in the space. In 2024, Illumina launched a new oncology assay menu for the NovaSeq X Series, while Pacific Biosciences introduced a free HiFi long-read variant database to support rare disease research. QIAGEN also upgraded its QCI Interpret software, enhancing scalability and performance for high-throughput laboratories.

Future Outlook

As Saudi Arabia strengthens its healthcare infrastructure and invests in biotechnology research, the NGS market is poised for continued expansion. The country's focus on precision medicine, data-driven healthcare, and academic research collaboration will further accelerate adoption. By 2031, the Saudi Arabia NGS market will play a pivotal role in advancing genomic medicine, contributing significantly to early disease detection, personalized therapies, and improved patient care across the Kingdom.

Related Reports:

Asia-Pacific Next Generation Sequencing (NGS) Market: https://www.meticulousresearch.com/product/asia-pacific-next-generation-sequencing-market-5722
Saudi Arabia Medical Devices Market: https://www.meticulousresearch.com/product/saudi-arabia-medical-devices-market-6099
Next Generation Sequencing Services Market: https://www.meticulousresearch.com/product/next-generation-sequencing-services-market-5041

About Us:

We are a trusted research partner for leading businesses worldwide, empowering Fortune 500 organizations and emerging enterprises with actionable market intelligence tailored to drive revenue transformation and strategic growth. Our insights reveal forward-looking revenue opportunities, providing our clients with a competitive edge through a diverse suite of research solutions-syndicated reports, custom research, and direct analyst engagement.

Each year, we conduct over 300 syndicated studies and manage 60+ consulting engagements across eight key industry sectors and 20+ geographic markets. With a focus on solving the complex challenges facing global business leaders, our research enables informed decision-making that propels sustainable growth and operational excellence. We are dedicated to delivering high-impact solutions that transform business performance and fuel innovation in the competitive global marketplace.

Contact Us:

Meticulous Market Research Pvt. Ltd.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
Email- sales@meticulousresearch.com
USA: +1-646-781-8004
Europe: +44-203-868-8738
APAC: +91 744-7780008
Visit Our Website: https://www.meticulousresearch.com/
For Latest Update Follow Us:
LinkedIn- https://www.linkedin.com/company/meticulous-research

This release was published on openPR.